semaglutide natural alternatives for weight loss Guide to FDA-Approved Weight Loss

Basic metabolic panel and lipid panel Baseline plus periodic review at 4-week and 8-week marks

According to the SmPC, Wegovy commonly causes nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during dose escalation

Long-term therapy decisions should weigh oncological efficacy against risks of endometrial cancer, thromboembolism, and metabolic alterations

The initial muscle loss seen with GLP-1 RA treatment as well as the ongoing replacement of muscle with fat with treatment cycles involving treatment interruptions can result in unfavorable changes in body composition in patients with obesity that can have profoundly negative repercussions, and can exacerbate obesity-related metabolic and health concerns 14,15,16

Bad breath is not listed as an official adverse effect in the UK Summary of Product Characteristics for tirzepatide